242 related articles for article (PubMed ID: 21639875)
1. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study.
Allin KH; Nordestgaard BG; Flyger H; Bojesen SE
Breast Cancer Res; 2011 Jun; 13(3):R55. PubMed ID: 21639875
[TBL] [Abstract][Full Text] [Related]
2. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.
Pierce BL; Ballard-Barbash R; Bernstein L; Baumgartner RN; Neuhouser ML; Wener MH; Baumgartner KB; Gilliland FD; Sorensen BE; McTiernan A; Ulrich CM
J Clin Oncol; 2009 Jul; 27(21):3437-44. PubMed ID: 19470939
[TBL] [Abstract][Full Text] [Related]
3. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival.
Frydenberg H; Thune I; Lofterød T; Mortensen ES; Eggen AE; Risberg T; Wist EA; Flote VG; Furberg AS; Wilsgaard T; Akslen LA; McTiernan A
Breast Cancer Res Treat; 2016 Jan; 155(2):345-54. PubMed ID: 26740213
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer.
Andersen HH; Bojesen SE; Johansen JS; Ejlertsen B; Berg T; Tuxen M; Madsen K; Danø H; Flyger H; Jensen MB; Nielsen DL
Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):662-670. PubMed ID: 38358318
[TBL] [Abstract][Full Text] [Related]
5. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients.
Wulaningsih W; Holmberg L; Garmo H; Malmstrom H; Lambe M; Hammar N; Walldius G; Jungner I; Van Hemelrijck M
Carcinogenesis; 2015 Oct; 36(10):1121-8. PubMed ID: 26130675
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Propensity Score Matched Study of the Preoperative C-Reactive Protein to Albumin Ratio and Prognosis in Patients with Resectable Non-Metastatic Breast Cancer.
Zhou L; Ma S; Balde AI; Han S; Cai Z; Li Z
Med Sci Monit; 2019 Jun; 25():4342-4352. PubMed ID: 31182704
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
[TBL] [Abstract][Full Text] [Related]
8. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein level on admission and time to and cause of death in patients hospitalized for acute heart failure.
Minami Y; Kajimoto K; Sato N; Hagiwara N; Takano T;
Eur Heart J Qual Care Clin Outcomes; 2017 Apr; 3(2):148-156. PubMed ID: 28927169
[TBL] [Abstract][Full Text] [Related]
10. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer.
Caan BJ; Kwan ML; Hartzell G; Castillo A; Slattery ML; Sternfeld B; Weltzien E
Cancer Causes Control; 2008 Dec; 19(10):1319-28. PubMed ID: 18752034
[TBL] [Abstract][Full Text] [Related]
11. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study.
Yang JR; Xu JY; Chen GC; Yu N; Yang J; Zeng DX; Gu MJ; Li DP; Zhang YS; Qin LQ
Sci Rep; 2019 May; 9(1):8143. PubMed ID: 31148582
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population.
Allin KH; Bojesen SE; Nordestgaard BG
Int J Cancer; 2016 Oct; 139(7):1493-500. PubMed ID: 27194008
[TBL] [Abstract][Full Text] [Related]
13. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
14. Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study.
Yao S; Kwan ML; Ergas IJ; Roh JM; Cheng TD; Hong CC; McCann SE; Tang L; Davis W; Liu S; Quesenberry CP; Lee MM; Ambrosone CB; Kushi LH
JAMA Oncol; 2017 Mar; 3(3):351-357. PubMed ID: 27832250
[TBL] [Abstract][Full Text] [Related]
15. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
16. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey.
Bittoni MA; Focht BC; Clinton SK; Buckworth J; Harris RE
Int J Oncol; 2015 Oct; 47(4):1537-44. PubMed ID: 26323323
[TBL] [Abstract][Full Text] [Related]
18. Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study.
Villaseñor A; Flatt SW; Marinac C; Natarajan L; Pierce JP; Patterson RE
Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):189-99. PubMed ID: 24220913
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
